Sekijima Y - Search Results

1

Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.

Schonhoft JD, Monteiro C, Plate L, Eisele YS, Kelly JM, Boland D, Parker CG, Cravatt BF, Teruya S, Helmke S, Maurer M, Berk J, Sekijima Y, Novais M, Coelho T, Powers ET, Kelly JW. Schonhoft JD, et al. Among authors: sekijima y. Sci Transl Med. 2017 Sep 13;9(407):eaam7621. doi: 10.1126/scitranslmed.aam7621. Sci Transl Med. 2017. PMID: 28904227 Free PMC article.

2

Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.

Sekijima Y, Hammarström P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW. Sekijima Y, et al. Lab Invest. 2003 Mar;83(3):409-17. doi: 10.1097/01.lab.0000059937.11023.1f. Lab Invest. 2003. PMID: 12649341 Free article.

3

D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?

Hammarström P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, Altland K, Garzuly F, Budka H, Kelly JW. Hammarström P, et al. Among authors: sekijima y. Biochemistry. 2003 Jun 10;42(22):6656-63. doi: 10.1021/bi027319b. Biochemistry. 2003. PMID: 12779320

4

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.

Miller SR, Sekijima Y, Kelly JW. Miller SR, et al. Among authors: sekijima y. Lab Invest. 2004 May;84(5):545-52. doi: 10.1038/labinvest.3700059. Lab Invest. 2004. PMID: 14968122 Free article.

5

The biological and chemical basis for tissue-selective amyloid disease.

Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. Sekijima Y, et al. Cell. 2005 Apr 8;121(1):73-85. doi: 10.1016/j.cell.2005.01.018. Cell. 2005. PMID: 15820680 Free article.

6

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Johnson SM, et al. Among authors: sekijima y. Acc Chem Res. 2005 Dec;38(12):911-21. doi: 10.1021/ar020073i. Acc Chem Res. 2005. PMID: 16359163 Review.

7

Biochemical characteristics of variant transthyretins causing hereditary leptomeningeal amyloidosis.

Mitsuhashi S, Yazaki M, Tokuda T, Sekijima Y, Washimi Y, Shimizu Y, Ando Y, Benson MD, Ikeda S. Mitsuhashi S, et al. Among authors: sekijima y. Amyloid. 2005 Dec;12(4):216-25. doi: 10.1080/13506120500352404. Amyloid. 2005. PMID: 16399646

8

R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.

Sekijima Y, Dendle MT, Wiseman RL, White JT, D'Haeze W, Kelly JW. Sekijima Y, et al. Amyloid. 2006 Jun;13(2):57-66. doi: 10.1080/13506120600722449. Amyloid. 2006. PMID: 16911959

9

Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis.

Tojo K, Sekijima Y, Kelly JW, Ikeda S. Tojo K, et al. Among authors: sekijima y. Neurosci Res. 2006 Dec;56(4):441-9. doi: 10.1016/j.neures.2006.08.014. Epub 2006 Oct 6. Neurosci Res. 2006. PMID: 17028027

10

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.

Sekijima Y, Dendle MA, Kelly JW. Sekijima Y, et al. Amyloid. 2006 Dec;13(4):236-49. doi: 10.1080/13506120600960882. Amyloid. 2006. PMID: 17107884 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

319 results

Search Page

Filters